Related Experiment Video
Updated: Jul 27, 2025
A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program
Published on: April 19, 2019
Analysis of the evolocumab (Repatha®) patient support program for patients with cardiovascular disease in Colombia
Ángel Alberto García-Peña1, Mariana Pineda-Posada2, Carol Páez-Canro2
1Pontificia Universidad Javeriana, Hospital Universitario San Ignacio, Bogotá, Colombia.
Insights
This study on evolocumab treatment in Colombia found over 70% patient adherence, but administrative and medical issues often interrupted treatment. Understanding these barriers is key for improving cardiovascular care.
Area of Science:
- Cardiology
- Pharmacoeconomics
- Public Health
Background:
- Cardiovascular diseases (CVDs) are a leading global cause of mortality.
- Patient support programs (PSPs) are crucial for managing chronic conditions like dyslipidemia.
- Evolocumab, a PCSK9 inhibitor, is used to manage hyperlipidemia.
Purpose of the Study:
- To describe patient demographics and treatment patterns in Colombia's evolocumab PSP.
- To assess self-reported compliance and persistence with evolocumab therapy.
- To identify factors associated with non-adherence to evolocumab treatment.
Main Methods:
- Retrospective analysis of data from patients in the evolocumab PSP (2017-2021).
- Inclusion of 930 patients with demographic and treatment data.
- Calculation of mean compliance and persistence rates.
Main Results:
- The study included 930 patients (mean age 65.1 years, 49.1% female).
- Mean compliance rate was 70.5%, with 40.5% of patients exceeding 80% compliance.
- Persistence rate was 87.8% among 739 analyzed patients; 93.7% reported adverse events (mostly non-serious).
Conclusions:
- This is the first real-world study on evolocumab PSPs in Colombia for dyslipidemia.
- Overall adherence exceeded 70%, comparable to other PCSK9 inhibitor studies.
- Administrative and medical reasons significantly contributed to treatment non-adherence.
Background:
Cardiovascular diseases are considered the leading cause of death globally. This study describes the demographic characteristics, treatment patterns, self-reported compliance and persistence, and to explore variables related to non-adherence of patients enrolled in the cardiovascular patient support program (PSP) for evolocumab treatment in Colombia.
Methods:
This retrospective observational of the data registry of patients who entered the evolocumab PSP program.
Results:
The analysis included 930 patients enrolled in the PSP (2017-2021). Mean age was 65.1 (SD±13.1) and49.1% patients were female. The mean compliance rate to evolocumab treatment was 70.5% (SD±21.8). A total of 367 patients (40.5%) reported compliance higher than 80%. Persistence analysis included 739 patients (81.5%) where 87.8% of these patients were considered persistent to treatment. A total of 871 patients (93.7%) reported the occurrence of at least one adverse event during the follow-up period (mostly non-serious).
Conclusion:
This is the first real-life study describing patient characteristics, compliance and continuity of treatment for dyslipidemia in a patient support program in Colombia. The overall adherence found was higher than 70%; similar to findings reported in other real-life studies with iPCSK9. However, the reasons for low compliance were different, highlighting the high number of administrative and medical reasons for suspension or abandonment of treatment with evolocumab.
More Related Videos
04:53A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
07:51Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
Related Concept Videos
01:26Coronary Artery Disease IV: Preventive Measures
01:11Clinical Trials: Overview
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:19Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...